Positive data on Kerendia in chronic kidney disease and type 2 diabetes

Late-breaking data presented today at the European Society of Cardiology Congress 2022 highlight the potential of German pharm major Bayer’s (BAYN: DE) Kerendia (finerenone), compared to placebo, to significantly reduce the incidence of sudden cardiac death across a broad range of patients with early to late-stage chronic kidney disease (CKD) and type 2 diabetes (T2D).